PURPOSE: To determine whether the number of lymph nodes (LNs) examined is associated with outcomes in patients without nodal metastasis after radical cystectomy (RC). PATIENTS AND METHODS: We retrospectively analyzed data from 4,188 patients treated at 12 centers with RC and pelvic lymphadenectomy without neo-adjuvant chemotherapy for urothelial carcinoma of the bladder (UCB). Outcomes of patients without LN metastasis (n = 3,088) were examined according to the LN yield analyzed as continuous variable, tertiles, and using the cutoffs of ≥ 9 and ≥ 20. RESULTS: The median nodal yield was 18 (range 1-123; IQR:20). A total of 2591 (84 %) and 1445 (47 %) patients had a LN yield ≥ 9 and ≥ 20, respectively. Median follow-up was 47 months (IQR:70). In multivariable analyses that adjusted for the standard clinicopathologic factors, higher LN yield was associated with a decreased risk of disease recurrence (continuous: HR = 0.996, p = 0.05; 3rd vs 1st tertile: HR = 0.853, p = 0.048; cutoff ≥ 20: HR = 0.851, p = 0.032). In the subgroups of patients with muscle-invasive UCB or those with ≥ 9 LN removed, LN yield was not associated with outcomes (p values >0.05). CONCLUSIONS: In this large multicenter cohort of patients with node-negative UCB, higher nodal yield improved recurrence-free survival when all patients were analyzed. Patients with a high LN yield (≥ 20 LN removed or 3rd tertile) had the largest benefit. The lack of prognostic significance of LN yield in patients with muscle-invasive UCB or those stratified by 9 LNs removed suggests that this effect is weak. Further prospective studies are needed to help identify preoperatively the optimal template for each patient.
PURPOSE: To determine whether the number of lymph nodes (LNs) examined is associated with outcomes in patients without nodal metastasis after radical cystectomy (RC). PATIENTS AND METHODS: We retrospectively analyzed data from 4,188 patients treated at 12 centers with RC and pelvic lymphadenectomy without neo-adjuvant chemotherapy for urothelial carcinoma of the bladder (UCB). Outcomes of patients without LN metastasis (n = 3,088) were examined according to the LN yield analyzed as continuous variable, tertiles, and using the cutoffs of ≥ 9 and ≥ 20. RESULTS: The median nodal yield was 18 (range 1-123; IQR:20). A total of 2591 (84 %) and 1445 (47 %) patients had a LN yield ≥ 9 and ≥ 20, respectively. Median follow-up was 47 months (IQR:70). In multivariable analyses that adjusted for the standard clinicopathologic factors, higher LN yield was associated with a decreased risk of disease recurrence (continuous: HR = 0.996, p = 0.05; 3rd vs 1st tertile: HR = 0.853, p = 0.048; cutoff ≥ 20: HR = 0.851, p = 0.032). In the subgroups of patients with muscle-invasive UCB or those with ≥ 9 LN removed, LN yield was not associated with outcomes (p values >0.05). CONCLUSIONS: In this large multicenter cohort of patients with node-negative UCB, higher nodal yield improved recurrence-free survival when all patients were analyzed. Patients with a high LN yield (≥ 20 LN removed or 3rd tertile) had the largest benefit. The lack of prognostic significance of LN yield in patients with muscle-invasive UCB or those stratified by 9 LNs removed suggests that this effect is weak. Further prospective studies are needed to help identify preoperatively the optimal template for each patient.
Authors: Shahrokh F Shariat; Pierre I Karakiewicz; Ganesh S Palapattu; Gilad E Amiel; Yair Lotan; Craig G Rogers; Amnon Vazina; Patrick J Bastian; Amit Gupta; Arthur I Sagalowsky; Mark Schoenberg; Seth P Lerner Journal: Clin Cancer Res Date: 2006-11-15 Impact factor: 12.531
Authors: Alexander Karl; Peter R Carroll; Jürgen E Gschwend; Ruth Knüchel; Francesco Montorsi; Christian G Stief; Urs E Studer Journal: Eur Urol Date: 2009-01-13 Impact factor: 20.096
Authors: Shahrokh F Shariat; Martine P Roudier; George E Wilcox; Michael W Kattan; Peter T Scardino; Robert L Vessella; Sibel Erdamar; Cuong Nguyen; Thomas M Wheeler; Kevin M Slawin Journal: Cancer Res Date: 2003-08-01 Impact factor: 12.701
Authors: Lars Weisbach; Roland Dahlem; Giuseppe Simone; Jens Hansen; Armin Soave; Oliver Engel; Felix K Chun; Shahrokh F Shariat; Margit Fisch; Michael Rink Journal: Int Urol Nephrol Date: 2013-07-25 Impact factor: 2.370
Authors: Michael Ahdoot; Leanne Almario; Hiwot Araya; Jonas Busch; Simon Conti; Mark L Gonzalgo Journal: World J Urol Date: 2014-01-28 Impact factor: 4.226
Authors: Emily M Rios; Mitchell A Parma; Roman A Fernandez; Timothy N Clinton; Ryan M Reyes; Dharam Kaushik; Deepak Pruthi; Ahmed M Mansour; Neelam Mukherjee; Jon Gelfond; Karen M Wheeler; Robert S Svatek Journal: Urology Date: 2019-12-27 Impact factor: 2.649